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Lymphatic filariasis (LF) is one of the most debilitating and disfiguring diseases common in Ethiopia and is 
caused by Wuchereria bancrofti.  Mapping for LF has shown that 70 woredas (districts) are endemic and 5.9 mil-
lion people are estimated to be at risk. The national government’s LF elimination programme commenced in 2009 
in 5 districts integrated with the onchocerciasis programme. The programme developed gradually and has shown 
significant progress over the past 6 years, reaching 100% geographical coverage for mass drug administration 
(MDA) by 2016. To comply with the global LF elimination goals an integrated morbidity management and disabil-
ity prevention (MMDP) guideline and a burden assessment programme has also been developed; MMDP protocols 
and a hydrocoele surgical handbook produced for country-wide use. In Ethiopia, almost all LF endemic districts 
are co-endemic with malaria and vector control aspects of the activities are conducted in the context of malaria 
programme as the vectors for both diseases are mosquitoes. In order to monitor the elimination, 11 sentinel and 
spot-check sites have been established and baseline information has been collected. Although significant achieve-
ments have been achieved in the scale up of the LF elimination programme, there is still a need to strengthen op-
erational research to generate programme-relevant evidence, to increase access to morbidity management ser-
vices, and to improve monitoring and evaluation of the LF programme. However, the current status of implementa-
tion of the LF national programme indicates that Ethiopia is poised to achieve the 2020 goal of elimination of LF. 
Nevertheless, to achieve this goal, high and sustained treatment coverage and strong monitoring and evaluation of 
the programme are essential.  
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INTRODUCTION 
 
Lymphatic filariasis (LF) is a neglected tropical disease (NTD) caused by three species of filarial worm: Wuchere-
ria bancrofti, Brugia malayi and Brugia timori. LF is prevalent in 73 tropical and sub-tropical countries (1), and is 
transmitted via the bite of an infected mosquito. Whilst infection can be acquired during childhood, the overt 
chronic manifestations of the disease may occur in later life. Those clinical manifestations of greatest public health 
significance are lymphoedema of the limbs, genital disease (most commonly hydrocoele) and recurrent acute at-
tacks. Estimates suggest that 19.4 million men worldwide suffer from hydrocoele and almost 16.7 million individu-
als, mostly women, have lymphoedema of the leg (1); although these estimates probably do not reflect the true 
magnitude of the global burden from this infection.  
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Due to these disfiguring clinical manifestations, LF is regarded as one of the leading causes of global disability. 
Following the World Health Organization (WHO) classification of LF as a potentially eradicable disease, the 
World Health Assembly (WHA) adopted Resolution WHA 50.29 in 1997, which called on Member States to initi-
ate steps to eliminate LF as a public health problem (2). Three years later, the WHO launched the Global Pro-
gramme to Eliminate LF (GPELF) with each endemic member country expected to set up a programme for elimi-
nation of the disease. The two key components of the strategy being to interrupt transmission of the disease 
through mass drug administration (MDA) with Ivermectin and Albendazole drugs, and to prevent disability and 





To date, a strong progress has been made in terms of MDA, with 18 countries having completed treatment and a 
further 22 having delivered MDA in all endemic areas. However, with only 24 out of 73 endemic countries re-
ported to have an active morbidity management and disability prevention (MMDP) component in their LF pro-
grammes, further efforts are needed to ensure greater access to care for those disabled and disfigured by the clini-
cal manifestations of LF (4). Ethiopia initiated the LF elimination programme in 2009. This manuscript describes 
the LF programme in Ethiopia documenting the milestones, and lessons learnt through the implementation of the 
programme.  
 
Epidemiology and geographical distribution of LF in Ethiopia: LF is one of the most debilitating and disfiguring 
diseases common in Ethiopia and in this country is caused by Wuchereria bancrofti (5). Anopheles species of mos-
quitoes are the main vectors for LF transmission in Ethiopia (6). 
 
Tremendous progress has been made on mapping of LF in Ethiopia. The School of Medicine at Addis Ababa Uni-
versity together with the Carter Center and the Federal Ministry of Health (FMOH) initiated the mapping of LF in 
112 districts from 2008 to 2010, in the following 5 regions: Benishangul-Gumuz, Gambella, SNNPR (i.e. Keffa, 
Sheka, and Bench-Maji zones), Oromia (i.e. West Wollega zone), and Amhara (i.e. North Gondar zone). The map-
ping included 11,685 individuals living in 125 villages in 112 districts. The result of these surveys indicates that 
LF is endemic in 34 districts of the 5 regions.  The overall prevalence rate was 3.7%, but high geographical cluster-
ing and variation in prevalence (ranging from 0% to more than 50%) was found (7).  
 
In 2013, a nationwide integrated mapping of LF and podoconiosis (a disease that also causes lymphoedema and 
elephantiasis) in 658 districts of 7 regional states and 2 city administrations was conducted. Overall, 130,166 peo-
ple were examined in 1,315 communities in the 658 districts. In total, 140 people were found to be positive for 
circulating LF antigen by immuno-chromatographic card test (ICT) in 89 communities. According to the results, 
75 of the 658 districts surveyed in the 9 regions were found to be LF endemic[6]. Of these, 45 had a borderline 
result, where  validation of the results was required before deciding to scale up the MDA (6). For this reason, the 
FMOH in collaboration with the Ethiopian Public Health Institute (EPHI) jointly conducted a validation survey in 
these 45 districts and found that only 3 districts were endemic for LF.  
 
Together, the LF mapping results indicate that infection is endemic in 70 districts in 6 regions summarized in Ta-























* Remapping of 45 districts with borderline results reduced the total number of LF endemic districts to 3.  
  The estimated total population at risk of LF for the 70 endemic districts in Ethiopia is 5.9 million (Table 2 & Fig-
ure 1) (8). Among the 70 LF-endemic districts, 29 are co-endemic with podoconiosis, 45 are co-endemic with on-
chocerciasis and 69 are co-endemic with soil transmitted helminthes (STH).  
 




































Figure 1. Distribution of Lymphatic Filariasis, Ethiopia 
 
 
Region No. of Endemic Districts 







Mapped districts Endemic districts Prevalence 
Method of  
Survey 
Year of survey and ref-
erence 
112 34 0% to 50% ICT cards 2012, Shiferaw et al (7) 
658 75 0% to 5.8% ICT cards 2014, Rebollo et al (6) 
45* 3 0% to 2.1% ICT cards 2016, Unpublished report 
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Though detailed information about lymphoedema and hydrocoele burden is not yet available, the first phase of the 
mapping surveys (2008-2010) carried out in a sample population of 11,685 individuals living in 112 districts of 
western Ethiopia, indicated that the prevalence of hydrocoele (in males) and limb lymphoedema was 0.8% and 


























Figure 2: Lymphatic Filariais programme milestones 
 
Programme Implementation: The NTD team under the disease prevention and control directorate has formulated a 
national master plan (2016-2020) (8) for the Elimination of Lymphatic Filariasis and other NTDs in Ethiopia and 
has established a National Task Force (Figure 2). In line with the global strategy, the government initiated the im-
plementation of the national LF elimination programme in 2009, integrated with the onchocerciasis control pro-
gramme, to undertake programmes aimed at controlling and eliminating lymphatic filariasis as a public health 
problem in Ethiopia by 2020. 
 
MDA Process: Medication has been distributed by the health development army who has been trained in the cor-
rect ways of administering the tablets to endemic communities. The approach used in most of the communities 
included a number of training sessions prior to each activity. Zonal-level ‘training of trainers’ style training fol-
lowed by district-level training has been conducted every year before MDA. This training is then cascaded to the 
community-level each year. This is the most appropriate remedy to overcome the challenges posed by pastoralist 
populations and to reduce non-compliance. Training for community leaders is conducted to sensitize and educate 
them about LF, including how to organize the MDA. Training sessions on health communication are also organ-
ized in each community and focus on a number of key messages related to LF treatment, transmission, and preven-
tion, as well as the clinical manifestations of LF. Training is followed by an intense community mobilization cam-
paign using available media including banners, posters, audio spots on local radio stations, and messages delivered 
by megaphones to inform and encourage the population to participate in the MDA. Different types of posters have 
been distributed to each village and posted in a range of places to increase visibility. Community mobilization and 
sensitization is also conducted by health extension workers and the health development army at each village using 
mechanisms such as social and religious gatherings and local market places where people are gathered. The com-
munity elders and the community administration, as well as the community at large, are key players in facilitating 
the MDA activities. Finally, following the distribution, reported coverage data aggregated by age and gender is 
collected from each distribution post and submitted to the FMOH.  
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Mass Drug Administration: The programme started slowly, with only 5 districts in Gambella region being treated 
through MDA, giving geographical coverage of only 7% in 2009. However, there has been significant progress 
over the past 6 years with all endemic districts (70 in total) expected to implement MDA by 2016, thus giving 
100% geographical coverage. The number of districts covered by MDA each year since 2009 and the cumulative 




















Figure3. Percentage distribution of districts covered by MDA from 2009-2016. 
Figure 4. Map showing the geographic coverage for mass drug administration for Lymphatic Filariasis 
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With the gradual scale-up of geographical coverage, the number of people targeted and treated each year has in-
creased notably. The annual treatment coverage rates are shown in Table 3, including data from 2009 to 2015. 
Overall, satisfactory programme coverage rates have been achieved each year in the targeted areas since 2009 and 
maintained at a high level since 2015, ranging from 72.7% to over 87%. In subsequent years, the FMOH with part-
ner support has made significant achievements in the scaling up of treatments as shown in Table 3. LF treatment 
has increased rapidly with 77,424 individuals treated in 2009 to 3.7 million treated by end of 2015, with the aver-
age reported treatment coverage reaching 87% in 2015. Most notably, the national epidemiological coverage for 
LF steadily increased over the years to reach over 65%, treating around 1.6 million people each year since 2009 to 
the end of 2015 (Table 3, Figure 5).  
 
































Figure 5. Treatment coverage for lymphatic filariasis mass drug administration  
 
 
Year # Targeted # Treated Therapeutic/Reported 
Coverage 
2009 99,037 77,422 78% 
2010 101,013 73,435 73% 
2011 103,896 84,929 82% 
2012 920,032 711,701 77% 
2013 1,872,078 1,422,298 76% 
2014 1,887,095 1,533,916 81% 
2015 3,732,694 3,205,901 86% 
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Morbidity Management: In addition to MDA, morbidity management is another component of the LF elimination 
programme in Ethiopia. To begin to initiate the scale-up of integrated morbidity management for LF and podoco-
niosis, an integrated (MMDP guideline has been developed for both diseases. The MMDP guideline provides prac-
tical guidance on patient management and disability prevention based on practical in-country field experiences. It 
provides guidance on planning, implementation and monitoring of MMDP activities and also provides the best 
available information on MMDP for acute dermatolymphangioadenitis (ADLA; acute attacks), lymphoedema or 
elephantiasis, and hydrocoele. Furthermore, the FMOH in collaboration with partners has prepared a hydrocoele 
surgical handbook to standardize and scale up hydrocoele surgery services in the endemic districts. Together with 
the Surgical Society of Ethiopia and partners, the FMOH conducted a hydrocoele surgery training and 15 surgeons 
were trained and 18 patients treated during the session.  
 
To estimate and identify lymphoedema and hydrocoele cases, a burden assessment protocol has been developed 
and so far, conducted in 35 districts (50% of endemic districts). The burden assessment is important to identify 
patients with lymphoedema and hydrocoele for prioritization of MMDP resources. The burden assessment was 
conducted through a complete census of every household in the endemic districts by trained health extension work-
ers. The FMOH is working to ensure 100% access to lymphoedema management services in all endemic districts 
by 2020. Currently, there are 7 districts (10%) providing lymphoedema management integrated with podoconiosis 
treatment.  
 
Vector Control: Ethiopia has fostered a robust long-lasting insecticidal net (LLIN) distribution and indoor residual 
spraying (IRS) programme. The linkage between LF prevention and sleeping under a bed net is well-understood. 
The major malaria and LF vector in Ethiopia is the Anopheles species (9). Therefore, malaria interventions will 
also play an important role in the prevention of LF. The FMOH conducted a malaria stratification study using 
transmission intensity data (annual parasite incidence per 1000 population -API), altitude information and expert 
opinion (10). As per this stratification, 67 (96%) districts are co-endemic with low, moderate and high malaria en-
demic districts. Moderate malaria endemic districts are targeted for LLINs while high endemic districts are tar-
geted for both LLINs and IRS[10]. Among the 67 co-endemic districts 46 (66%) are eligible for LLINs and 25 
(36%) are targeted for both LLINs and IRS intervention.  
 
Monitoring and Evaluation: Sentinel and spot-check sites are important to provide programme managers with 
reasonably accurate information on the trend of infection over the course of the programme (11). Therefore, in 
order to assess the impact of MDA, sentinel sites were established in 11 districts and baseline information col-
lected. WHO recommends that at least 1 sentinel site should be identified for each implementation unit (IU) or at a 
minimum, at least 1 site per 1,000,000 population in the IU (11). In Ethiopia, the sentinel sites are located in the 








































Partnership: The FMOH provides overall policy direction, as well as coordinating and creating an enabling envi-
ronment so that stakeholders and partners can contribute to the country’s efforts towards achieving the envisaged 
elimination goal by 2020. It officiates the endemicity and disease burden data not only to help evidence-informed 
planning and resource mobilization, but also to set benchmarks to monitor and evaluate the programme. The Min-
istry further plays a pivotal role in harmonizing the contributions of stakeholders and partners while enhancing 
complementarity and avoiding duplication of efforts.  
 
To strengthen the LF elimination programme, FMOH established and supports a Technical Working Group (TWG) 
for LF and podoconiosis. The members of the TWG include stakeholders, implementing partners, research insti-
tutes and a local university. The TWG, under the auspices of the National NTD Taskforce (NNTF), advises the 
Ministry on strategic issues. By doing so, they set high standards to guide programming through self-updating on 
new developments and proposing revisions for policy consideration, make expertise contributions in developing 
and harmonizing national strategic plans, technical guidelines and tools, reviewing progress in treatment coverage 
and disease burden to assure that the country is on-track towards reaching set targets, design mechanisms to docu-
ment and disseminate research findings, and analyzing best practices and lessons learnt to improve programme 
performance. The TWG also helps in identifying and materializing priority operational and implementation re-
search to ensure policy and programme quality. Together with  the implementing partners, the members also help 
in documenting best practices for adoption by others.  
 
The main LF programme implementing partners include The Carter Center (TCC), Research Triangle Institute 
(RTI), and  the Centre for Neglected Tropical Diseases at the Liverpool School of Tropical Medicine (CNTD/
LSTM). TCC and RTI support both LF and onchocerciasis endemic regions while CNTD supports largely LF en-
demic regions. Out of 70 endemic districts, TCC has supported MDA since 2009 in 25 districts in Gambella, Ben-
ishangul-Gumuz, SNNP and Amhara regions; RTI supports 23 districts in Oromia and Benishangul-Gumuz re-
gions through Light for the World and the Fred Hollows Foundation, and CNTD supports 22 districts in SNNP, 
Amhara and Oromia regions (Figure 6). RTI and CNTD have further made the necessary preparations to support 
MMDP interventions in LF endemic districts of Benishangul-Gumuz, Tigray and Oromia regions and SNNPR. The 
implementing partners closely work with the Ministry and Regional Health Bureaus in designing and managing 
model programmes that can serve for training, cross-learning and scaling up.   




Year of Survey, 
MF 
1 Metema 23/100(23) 2008-2009 4/360(1.1) 2011 
2 Quarra 17/100(17) 2008-2009 0/304(0) 2011 
3 Guba 55/100(55) 2008-2009 32/404(7.9) 2011 
4 Meneat Goldiya 27/100(27) 2008-2009 0/608(0) 2011 
5 Maji 21/100(21) 2008-2009 1/308(0.32) 2011 
6 Abobo 81/303(26.7) 2008-2009 0/311(0) 2014 
7 Sherkole  19/306(6.2) 2012 - - 
8 Srba Abay 73/300(24.3) 2012 - - 
9 Mao Komo 3/273(1.1) 2012 - - 
10 Gambela Zuria 66/193(34) 2008-2009 0/201(0) 2014 
11 Harana Buluk 2/363(0.6) 2014 - - 
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The WHO Country Office is also a member of the TWG and provides technical support to the Ministry as well as 
regions. The Ethiopian Public Health Institute (EPHI) has played a prominent role in LF mapping throughout the 
country between 2013 and 2016. Furthermore the Institute is a key partner in generating evidence through sentinel 
surveillance sites that are distributed throughout the endemic districts.  
 
Universities and other research institutions are continuously contributing in addressing the knowledge gap on the 
disease, not only by gathering and disseminating new knowledge from elsewhere, but also by undertaking small 
and large scale studies in the different parts of the country. They are further contributing in equipping their para-
medical and medical students with basic knowledge and skills. 
 
Civil society organizations, such as the Surgical Society of Ethiopia (SSE), are also supporting the elimination 
efforts through preparing disease management manuals, developing skills of surgeons and other health workers on 
innovative approaches, and promoting quality assurance through close follow-up of both surgeons’ performance 
and treatment outcomes. At present, SSE is working with the Ministry, RTI and CNTD to organize surgical camps 
in high disease burden areas, using the model session first instigated in Hawassa in 2015, so as to accelerate allevi-
ating both the sufferings of people and reducing the disease burden.  
 
Last but not least, donors have generously funded innovative LF management approaches. They have made it pos-
sible to harmonizing resources and further advocating for leveraging resources from other potential sources to fill 







































Major Programme Implementation Challenges towards LF elimination: Ethiopia successfully scaled up the LF 
elimination programme over the last few years. Despite these significant achievements in the scale up and a greater 
national momentum for LF elimination, several significant issues remain to be resolved. First, the national pro-
gramme should be backed up by strong operational research to generate evidence and inform the national pro-
gramme. As this programme is relatively new in the country, operational challenges should be tackled with innova-
tive approaches. Secondly, the 100% geographical coverage through MDA is a very encouraging result. The other 
pillar of the elimination, i.e. access to MMDP services continues to be a challenge. Burden assessments in all en-
demic districts should be completed and the morbidity management services should be accessible to patients re-
quiring them. Thirdly, strong monitoring and evaluation of the LF programme is a requirement for monitoring pro-
gress towards elimination and achieving the 2020 goals. Sentinel and spot-check sites should be established as per 
the WHO guidelines.  
 
Conclusion: The mapping of LF nationwide has been completed. The results indicated that LF is endemic in 70 
districts in Ethiopia with 5.9 million people at risk of the disease and thus in need of annual treatment. To this end 
Ethiopia began the national LF elimination programme in 2009. In 2016, the programme aimed to achieve LF 
MDA coverage in all endemic districts with 100% geographical coverage. The programme has demonstrated 
strong implementation capacity, coordination mechanisms and successful partnership over the last few years. The 
current implementation of the programme indicates that Ethiopia is poised to achieve the 2020 goal of elimination 
of LF. Nonetheless this is contingent upon sustained treatment coverage, strong monitoring and evaluation of pro-
gress and strong evidence generation to inform the national programme. Building on the success so far, the pro-
gramme should accelerate its momentum while maintaining quality. Successful elimination programmes of LF 
depend upon high and sustained treatment coverage and strong monitoring and evaluation of the programme. 
Ethiopia should draw lessons from other successful LF elimination programmes elsewhere, whilst capitalizing on 
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